Navigation Links
CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
Date:7/10/2009

VIENNA, Va., July 10 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), a late stage cancer immunotherapy company, announced today that Dr. Eyal Talor, CEL-SCI's Senior Vice President of Research and Manufacturing, has been invited to present to the NIH, NCI's Clinical Center and the Center for Human Immunology, NERD (New Research and Development) Seminar Series, which will take place on Friday July 10, 2009 at the NIH's Clinical Center located at the main NIH campus, on 9000 Rockville Pike, Bethesda, MD. The title of Dr. Talor's presentation is: "Multikine: Cancer Immunotherapy; how to make immunotherapy for cancer work".

In the presentation, Dr. Talor will discuss Multikine's immunotherapy clinical program for cancer, the unique mechanism of action of Multikine (published in the Journal of Clinical Oncology) and the way Multikine imparts the patient's own immune response with the ability to mount a robust anti-tumor immune response against his/her tumor. Dr. Talor will also discuss the clinical findings from the different Multikine Phase II clinical trials which highlight the advantages that Multikine treatment provides for early disease management in newly diagnosed (treatment naive) patients with Squamous Cell Carcinoma of the Head and Neck. Early intervention in this disease is seen by many clinicians and researchers in the field as a key to improving disease outcome in these patients.

Dr. Talor will also discuss the objectives of the collaborative study between the NIH, NCI under a current Material Transfer Agreement. This work is aimed at elucidating the tumor microenvironment changes, at the molecular level, brought about by Multikine treatment of head and neck cancer patients. The CEL-SCI / NIH collaborative study will use samples collected from patients with a
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CEL-SCI Posts New Corporate Presentation to Website
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI Corporation Releases Letter to Shareholders
4. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
5. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
6. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
7. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
8. CEL-SCI Corporation Reports First Quarter Financial Results
9. CEL-SCI Corporation Announces 2007 Financial Results
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
11. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015  Rigrodsky & Long, P.A.: ... Inc. (NASDAQ GM: AERI )? , Did you purchase ... , Did you lose money in your investment in Aerie ... Rigrodsky & Long, P.A. , including ... announces that a complaint has been filed in the United States ...
(Date:5/6/2015)... South Africa , May 6, 2015 ... than HIV/AIDS, malaria and tuberculosis combined[1]. Approximately 40 percent of ... cured with the right treatment[3]. Together with Elekta, ministries of ... build up their radiation therapy infrastructures and save lives. ... would benefit from radiation therapy[4] during the course of their ...
(Date:5/6/2015)... Markets ( http://www.researchandmarkets.com/research/jskhnb/energy_based ) has announced the addition ... Business Report" report to their offering. The ... Canada , Japan , ... of World. Annual estimates and forecasts are provided for the ... provided for these markets. The global market is ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc. 2SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc. 3Elekta to bring cancer treatment to millions in Africa 2Elekta to bring cancer treatment to millions in Africa 3Elekta to bring cancer treatment to millions in Africa 4Energy based Ablation Devices - Global Strategic Business Report 2015: Increasing Incidence of Cancer Bodes Well For Energy Based Ablation Devices 2Energy based Ablation Devices - Global Strategic Business Report 2015: Increasing Incidence of Cancer Bodes Well For Energy Based Ablation Devices 3
(Date:5/6/2015)... Chesapeake Regional Medical Center is the ... acquire Intuitive Surgical, Inc.’s latest model of the ... enhanced surgical technique capabilities, which can be used ... spectrum of specialties. Its advancements allow patients less ... times. , “As the only independent, community-based hospital ...
(Date:5/6/2015)... May 06, 2015 The Beryl Institute ... of Patient Experience Journal (PXJ), an international, open ... around understanding and improving patient experience. The second volume ... experience conversation globally, helps align the voices engaged and ... , Published in association with The Beryl Institute, Volume ...
(Date:5/6/2015)... 06, 2015 Is Colorado’s legal cannabis ... month the Centennial State will mark the 18-month milestone ... to adults. And while Colorado’s legal marijuana industry has ... time, it’s also facing some new challenges. , For ... facing shortages, especially in the wake of last month’s ...
(Date:5/6/2015)... vcfo, a specialized consulting firm that provides ... to optimize business performance and productivity, announced the additions ... Scheaffer. Both Lynch and Scheaffer have more than 25 ... “We are delighted to add Jack and Mike to ... background in financial management and leadership, Mike and Jack ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto startup ... China, has successfully demonstrated a handheld real time quantitative-polymerase-chain-reaction ... Anitoa’s handheld qPCR is shown to be capable of ... hepatitis B, C, and E. Coli. This qPCR system ... and over 9 orders of magnitude dynamic range. ...
Breaking Medicine News(10 mins):Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 3Health News:vcfo Adds Two Senior Executives to Growing Team 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3
... is so much alike the code of humans, almost a ... And yet, // there are glaring differences, despite the 98% ... not a different set of genes that caused the difference, ... According to a latest theory on evolution, even small alterations ...
... many are not aware of the Medicare part D program’s guidelines. ... Roxbury Presbyterian Church was a great relief for them. ... the bus, which has been traversing New England cities and towns ... , The deadline to sign up for new prescription drug coverage ...
... Women with disproportionate or uneven breasts have a greater likelihood ... record any alterations or changes in the breast, the study ... conducted a study where mammograms of 252 women who developed ... healthy women. It was observed that, though breast cancer ...
... psychiatrist Dr Charles Reynolds at the University of Pittsburgh which ... , The study’s main aim was to analyze the ... people. It is one of the longest studies ever ... antidepressants for longer periods, perhaps even for life, in patients ...
... nominated to run the U.S. Food and Drug Administration, ... pressure while scientific decisions were being made//. He further ... medical endeavors, the appropriateness should also be taken into ... the FDA and Director of National Cancer Institute, would ...
... years old and two adults were placed under quarantine in ... part of Maharashtra. ,Tina Nanavade from Rawer taluka, ... was admitted to Nhavi Hospital on Sunday afternoon. Tami flu ... a possible bird-flu. ,Sarla More from Jamner, a ...
Cached Medicine News:Health News:Drugs Are Effective In Treating Depression and Preventing Recurrence 2Health News:FDA Nominee Says That He Is Not Influenced By Politics 2
... volume laboratories, as well as specialty labs, ... simplicity and flexibility needed to respond to ... Elecsys 1010 system enables operators to handle ... testing without sacrificing ease of operation or ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... System provides high-performance detection technologies to ... and therapeutic drugs. It also delivers ... that allow the laboratory to streamline ... This high-productivity design enables numerous functions ...
The Embla 384 cell washer is a top-loading, robotic-compatible microplate washer for high throughput screening. It is designed specifically for cell-based assays, which require a gentler wash, but ca...
Medicine Products: